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cGVHD. Interestingly, rapamycinpreventeddeath fromcGVHD
in that model, perhaps through in vivo expansion of Treg.419
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Graft-versus-host disease (GVHD) frequently causes
morbidity and mortality after allogeneic hematopoietic cell
transplantation (HCT). In HLA-identical HCT, GVHD results
from donor T cell recognition of minor histocompatibility (H)
antigens on recipient tissues. Complete T cell depletion (TCD)
of donor hematopoietic cell products is more effective than
pharmacologic immunosuppression for preventing GVHD,
but is complicated by delayed immune reconstitution and
consequent life-threatening infections. Approaches to HCT
that preferentially deplete T cells responsible for GVHD and
preserve pathogen-speciﬁc T cells may improve outcomes.
Mature CD3+CD8+ and CD3+CD4+ T cells can be classiﬁed into
CD45RA+CD62L+ naïve (TN) and CD45RO+ memory (TM)
subsets, the latter of which includes effector memory (TEM)
and central memory (TCM) T cells. Murine studies in MHC-
matched and emismatched models demonstrated that
transplanting TN cells causes severe GVHD, puriﬁed TCM
causes mild GVHD, and TEM do not cause GVHD. In vitro
studies have similarly demonstrated that human donor CD8+
T cells speciﬁc for recipient minor H antigens are found
predominantly within the TN cell subset. In sum, these data
suggest that selective TNcell depletion may alter the inci-
dence or severity of GVHD in human HCT.
We developed an effective process for engineering human
peripheral blood stem cell (PBSC) grafts that depletes
CD45RA+ TN and retains CD34+ stem cells and functional
CD45RO+ TM speciﬁc for diverse opportunistic pathogens.We
initiated a clinical trial to evaluate selective depletion of TN
cells from allogeneic PBSC for the prevention of GVHD in
patients with acute leukemia. Each of the ﬁrst 22 patients has
engrafted (median day 12), regimen-related toxicity has
been acceptable, T-cell numbers recover faster than reported
for TCD HCT (median 412 CD3+ T cells/ml on day 28), and
there is no increase in the rate of relapse, opportunistic
infections, or EBV reactivation compared to patients treated
with T cell replete PBSC grafts. Early onset gastrointestinal
symptoms that are compatible with mild acute GVHD occur
frequently, but rapidly respond to therapy, and most patients
have successfully tapered immunosuppression. T cell
responses to pathogens recover early after HCT. At a median
of 14 months follow-up, overall and disease free survival are
80% and 75% respectively, and the frequency and severity of
chronic GVHD is substantially reduced compared to recipi-
ents of T cell replete PBSC grafts.420
Adenovirus PCR-Positivity in Stool Precedes Intestinal
GRAFT Versus Host Disease After Allogeneic
Hematopoietic Stem Cell Transplantation
Jaap Boelens. Department of Pediatrics: Blood and Marrow
Transplantation Program, UMC Utrecht (Wilhelmina Children's
Hospital), Utrecht, NetherlandsIntroduction: Acute graft versus host disease (aGvHD) is
a common (20-50% of all HSCT recipients) and potentially
lethal complication after allogeneic hematopoietic stem cell
transplantation (HSCT). Risk factors for aGvhD include donor
source, preparative regimen and the degree of HLA-mis-
matching. Currently, there is increasing evidence that
(reactivation of) viral infection is a risk factor for aGvHD. We
hypothesized that the presence of viruses in the gastroin-
testinal tract, including AdV, triggers the initiation phase of
intestinal GvHD. Therefore we investigated the association
between viral PCR-positivity in stool prior to HSCT and the
occurrence of intestinal aGvHD.
Methods: We prospectively evaluated 27 consecutive pedi-
atric allogeneic HSCT patients from January ’09 until October
’10. Primary endpoint was the development of intestinal
aGvHD diagnosed according to Gluckbergs criteria and
conﬁrmed by histopathology. Follow-up ranged from 100 to
376 days or until death. Stool specimens were taken peri-
HSCT and analyzed for entero-, -noro-, astro-, -parecho- and
adenovirus, by real-time PCR. The association between fecal
PCR- positivity and intestinal aGvHD was analyzed using
Fisher's exact tests.
Results: Of the 27 patients that were evaluated, 6 (22%)
developed intestinal aGvHD after a median of 64 days (range,
38-74). Four (15%) patients died due to transplant related
complications or disease progression/relapse after 22-61
days. All patients with stool specimens positive for AdV (4/
27, 15%) developed intestinal aGvHD (versus 2 / 23 (9%)
patients without AdV in stool,P ¼ .001, positive predictive
value¼ 100%, negative predictive value¼ 91%). Four patients
were positive for other viruses but none of these developed
aGvHD. Interestingly, one patient became positive for AdV at
327 days post-SCT and developed chronic intestinal GvHD
after 476 days. AdV persisted in patient stool for more than
140 days, and preceded systemic infection: AdV was ﬁrst
detected in plasma on day 409 and loads raised from 482
copies/ml to 1.4*10.4 copies/ml on day 500.
Conclusion: AdV in stool prior to HSCT was associated with
intestinal acute GvHD. It supports the hypothesis that virally
induced tissue damage leads to inﬂux of inﬂammatory
mediators and ultimately activation and inﬂux of activated
cytotoxic T-cells involved in GvhD. Currently we perform
a prospective follow- up study. These results may impact
monitoring and treatment (preventive and curative) guide-
line/protocols.421
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Recent research has increased our understanding of
lymphocyte metabolism in vitro, but the metabolism of
lymphocytes activated in vivo remains poorly understood. To
evaluate this important issue further, we explored the
metabolism of proliferating, donor T lymphocytes seven days
after the initiation of graft versus-host disease (GVHD) in an
acute model of GVHD (B6 into B6D2F1). Donor T cells up-
regulated mRNA for fatty acid (FA) transport proteins (e.g.
Table
Fatty acid transport, oxidation, andmitochondrial biogenesis in GVHD Tcells
Parameter Naïve* GVHD P value
Fatty Acid Transport
Slc27a2 mRNA 1.0  0.8 42.0  6.7 1.0 >1.0
Transport (% cells
BoDipyHi)y
0.7  0.05 44.3  6.9 0.003
Fatty Acid Oxidation
CPT2 enzyme ratio 1.0  1.7 103  31 0.005
Oxidation (cpm x10-5)z 1.1  0.2 1.9  0.3 0.02
Mitochondrial Biogenesis
Mitochondrial Massx 47.6  14.2 66.3  5.9 0.04
Mitochondrial/nuclear
DNA
1.0  0.07 2.7  0.52 < 0.0001
PGC-1a ratio 1.0  1.3 3900  1200 0.005
* Naïve cells served as controls (values set to 1.0) for mRNA levels and all
ratios
y Uptake of BoDipyC1-C12, a fatty acid analog, was measured by ﬂow
cytometry
z Oxidation measured by the conversion of 3H-palmitate to 3H20,
expressed as cpm of 3H2O
x Mitochondrial mass measured as the % of cells Mitotracker GreenHi
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compared to resting (naïve) T cells (see Table). Donor T cells
also increased levels of enzymes necessary for FA oxidation
(e.g. CPT2) 100-fold and oxidized more FAs. Mitochondrial
mass (required for FA oxidation) increased in donor T cells, as
did the ratio of mitochondrial to nuclear DNA, and the
expression of PGC-1a, a key regulator of mitochondrial
biogenesis. Importantly, T cells proliferating during routine
immune reconstitution (following syngeneic BMT) mini-
mally increased FA transport (10% vs. 40% in GVHD T cells).
Finally, inhibition of FA oxidation in vivo, through irreversible
blockade of CPT1 with etomoxir, decreased the total number
of well-divided donor Tcells after a single dose. Furthermore,
two weeks of etomoxir treatment, beginning on day +7,
improved both GVHD clinical score (1.1 vs. 3.8 in untreated
animals, P ¼ .02) and weight loss at day 40. In total, these
data demonstrate that GVHD T cells up-regulate FA metab-
olism in vivo and that proliferating, donor cells can be
selectively eliminated through inhibition of FA oxidation. Our
data provide novel insights into the metabolism of lympho-
cytes activated in vivo and show that inhibition of FA
oxidationmay be a therapeutic target for the prevention and/
or treatment of GVHD.
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Acute graft-versus-host disease (aGvHD) of the gut based
only on clinical symptoms may be difﬁcult to distinguish
from other causes. Assessing response to treatment may be
hampered by persistent diarrhea resulting from damage to
the gut in the absence of ongoing aGvHD. Histological
examination of gut biopsies conﬁrm the diagnosis but are
invasive. We aimed to determine the importance of biopsies
to evaluate the response to treatment with mesenchymal
stromal cells (MSC) and assess the usefulness of biomarkers.In this study, 18 patients received MSC for severe steroid
refractory aGvHD of the gut (conﬁrmed by a biopsy in 16
patients). In 89% (n¼16) diarrhea persisted after the ﬁrst MSC
and a second (and in 3 cases a third) MSC infusion was
considered. A second gut biopsy was taken from 9 patients
before subsequent MSC infusion and in 6 of these biopsies
(67%) no signs of aGvHD were seen. The 3 patients with
biopsy conﬁrmed active aGvHD showed a response after
a subsequent MSC infusion. Nine out of 18 patients showed
a complete (CR), 4 a partial response (PR) and 5 no response
(NR) at 28 days after starting MSC therapy (1-3 infusions).
Our data suggests that without biopsy evaluation after MSC
infusion, the response to treatment may be underestimated
and over treatment occurs. In contrast patients with a posi-
tive biopsy may beneﬁt from additional MSC treatment.
However, a biopsy of children with aGvHD is not always
feasible. Therefore, the value of previously reported
biomarkers was assessed in our patient cohort (sIL2Ra,
sCK18F, sTNFR1). Patient samples were longitudinally
measured starting before SCT until 50 days after the last MSC
infusion. At the start of aGvHD, serum concentrations of sIL-
2Ra, sTNFR1 and soluble cytokeratin 18 fragment (sCK18F)
were signiﬁcantly elevated compared with samples before
onset. The response at day 28 can be predicted using sIL-2Ra
concentrations on day 7. Patients with CR/PR (n¼13) have
lower sIL-2Ra concentrations compared to non-responders
(n¼5) (P ¼ .015). The value of REG-3a in predicting the
occurrence of gut aGvHD and monitoring the effect of
treatment is currently being investigated.
In our opinion biomarkers can contribute to the diagnostic
process, but biopsy remains the golden standard for the
diagnosis and short term response to treatment of aGvHD.
Sequential biopsies should be included in randomized
controlled trials to validate the importance of biomarkers in
monitoring response to experimental cellular therapy.423
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